Altimmune

ALTPhase 2

Gaithersburg, United StatesFounded 1997altimmune.com

Altimmune leverages its proprietary peptide technology platform to design multi-targeted agonists that address complex metabolic disorders. The company's most advanced program, pemvidutide, has demonstrated promising weight loss and liver fat reduction in clinical studies, positioning it in the competitive but high-value obesity and MASH markets. Altimmune's strategy is to advance pemvidutide through clinical development, potentially seeking partnerships for later-stage trials and commercialization. The company operates as a lean, research-focused organization with key expertise in peptide chemistry and metabolic disease.

Market Cap

$434.6M

Founded

1997

Employees

50-100

Focus

BiologicsDrug DeliveryVaccines

ALT · Stock Price

USD 3.343.05 (-47.73%)

Historical price data

AI Company Overview

Technology Platform

Proprietary peptide engineering platform for designing multi-targeted agonists (e.g., GLP-1/glucagon) with optimized pharmacokinetics and hepato-directed activity for metabolic diseases.

Pipeline Snapshot

19 drugs in pipeline

Drug	Indication	Stage
Licensed seasonal influenza vaccine	Influenza	Approved
Pemvidutide	Alcohol Liver Disease	Phase 2
ALT-801	Obesity/Overweight	Phase 2
NasoVAX	Coronavirus Infection	Phase 2
Pemvidutide + Placebo	Non-Alcoholic Steatohepatitis (NASH)	Phase 2

Opportunities

Pemvidutide addresses two of the largest unmet medical needs in biopharma: obesity and MASH.

Positive Phase 2 data could position the asset for a lucrative partnership with a large pharmaceutical company capable of funding Phase 3 trials and global commercialization.

The favorable tolerability profile may offer a key differentiation in crowded markets.

Risk Factors

High clinical development risk as the company's value is concentrated in a single asset, pemvidutide.

Intense competition from well-funded giants like Novo Nordisk and Eli Lilly, as well as other biotechs.

Future dilution likely required to fund late-stage trials if not partnered.

Potential for regulatory hurdles requiring additional studies.

Competitive Landscape

Competes directly with Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) in obesity, and with Madrigal, 89bio, and Akero in MASH. Differentiation is based on pemvidutide's balanced GLP-1/glucagon dual agonist mechanism, which may offer benefits for lean mass preservation and energy expenditure, coupled with clinically demonstrated lower rates of gastrointestinal side effects.

Publications

Patents

Pipeline